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Cannabis is one of the most common and worldwide used 
illicit drug [1]. It was used far back in the Ancient China 
(2727 B.C.) [2]. The question about its harmful effect on 
human organism compared with it is possible useful impact 
and place in treatment psychiatric disorders and somatic 
diseases has never been more controversial nowadays.
Numerus studies have been conducted in this area and 
their results are subject of dispute. Some of them bring 
theories about a positive impact of cannabis on cogni-
tive functions [3, 4] and its place in treatment psychical 
disorders [5]. Much attention is being directed towards 
the active components of cannabis- cannabinoids such 
as cannabidiol (CBD), cannabigerol (CBG), and tetrahy-
drocannabivarin (THCV), because of their potential an-
tipsychotic properties [5, 6]. A large number of opposed 
studies gives arguments for the toxic impact of cannabis 
on neuroanatomic structures and brings out results about 
the atrophy of grey and white brain matter after a long 
term use of cannabis [7].
There are also studies which describe an atrophy of specific 
brain areas abounding in numerous cannabinoid CB1 recep-
tors such as the cingulate cortex and hippocampus [8, 9]. 
Among cannabis users, adolescents make the most sensitive 
group, in which the exposure to cannabis can cause severe 
and long term consequences in cognitive functions [10]. 
The adolescents brain is different from the adult’s because 
of the incomplete maturation of its structures and the brains 
also differ in anatomy (neuronal connections and morp-
hology) as well as neurochemistry [10]. Chronic exposure 
of the endocannabinoid system of adolescents to cannabis 
can dramatically influnce changes in brain maturation and 
cause long-lasting neurobiological changes that ultimately 
affect the cognitive function and increase the risk of deve-
loping a psychotic disorder [11−14]. 
The atrophy of grey and white matter is related to the 
frequency of cannabis use (how much and how often it 
is smoked) [15]. Chronic users have a significant atrophy 
of grey matter in brain abounding in cannabinoid re-
ceptors CB1, and it is associated with frequency of use 
and the numbers of the years of smoking cannabis [16].
In this case report, we present a young male patient who 
presents as a first psychoic episode and has confirmed 
brain atrophy after chronic use of cannabis. 
CASE REPORT
A 19 years old male patient, unemployed. Family ana-
mnesis does not show any records of psychiatric diseases. 
He was born as a younger of two children in the family 
of carefully monitored pregnancies. 
Abstract
The question of harmful effects of cannabis and its etiological relation to psychotic disorders versus its potential medical 
benefits has never been more present and controversial as it is today.
In our paper we present a young patient with first episode psychosis decompensation who admits heavy use of canna- 
bis use over a long period of time on a daily basis. Through a routine differential diagnostics, CT brain scan revealed  
a diffuse cerebral atrophy unrelated to any specific neurological disorder. 
We would like to point out probable causality of heavy cannabis use with clinical presentation and observed morpho-
logical changes. 
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Our patient started stammering at the age of three and 
he had been visiting a speech therapist for years. For 
the rest of the early and late childhood psychomotor 
development proceeded as normal. As a child he was 
very shy, having a hard time making friends. As he was 
finishing the elementary education, the family moved 
to another part of the city and it took him some time to 
adjust to new surroundings.
Not interested in learning, he finished the elementary 
school with difficulty, but in high school he adapted 
very well and made friends. He enrolled at a professional 
school. In the second grade of high school he smoked 
cannabis for the first time. In the beginning, it was smo-
ked occasionally at weekends with his new friends. For 
the last year and a half, he smoked cannabis every day. 
As he admitted, he smoked three or more “joints” daily.
The first psychic symptoms started about year and half 
before hospitalization. It began with hearing a kind of 
noise from time to time, but for the last six months these 
intensified, turning into imperative, commentary voices 
of religious character. He had difficulty falling asleep. To 
calm himself, as he was frightened and tired, he smoked 
more intensively, thinking that it might help him. He also 
started to withdraw. On the day of hospital admission, 
the patient came home, as his parents described, “stran-
ge and filthy”, displaying disorganized behavior after 
being away from home for a couple of hours. 
When addmited the patient was conscious, disoriented, 
he displayed markedly disorganized speech and behavior. 
His psychomotor functions were mildly enhanced, his 
mood dysphonic. Ductus of his speech was completely 
incoherent, he had dissociated judgment, distorted per-
ception of relations around him. He presented ideas of 
persecution and phenomena of derealization and mind 
reading. No aggressive behavior or suicidal thoughts 
were observed upon the admission. The patient verbali-
zed hallucinations in the form of voices that were giving 
him orders. Cognitive function was reduced secondarily, 
with low insight about his state.
In his somatic presentation we can point out the fresh 
bruises on dorsal side of both his fists made while pun-
ching a boxing bag repeatedly as he states in order to 
lower the tension.
During period of hospitalization, laboratory tests did 
not show any deviations (complete blood work, blood 
glucose, electrolytes, urea, hepatogram, creatinine, 
urin). The results of thyroid hormones test were within 
normal ranges and so were the EEG results. Neurora-
diological analysis was done, in which the MSCT of the 
brain displayed a mild difuse cerebral atrophy (Fig. 1). 
“Supratentorial atrophy in frontal apical and temporo-
parietal, liquor spaces of cortical sulci and subarahnoidal 
spaces are on both sides wider and somewhat deeper, 
also Sylvian fissures on the both sides.”
Psychological examination applied tools were: interview, 
RBS, BVRT, LB, MMPI, PIE, TNR, PTM. “In the intellectual 
function test patient scored on a level below the stan-
dard, probably compatible or somewhat reduced (psy-
chogenic) in comparison with the primary capacity. Mild 
disorders of recent memory/concentration of functional 
type were recorded. No graphomotorical deviations. No 
signs of psychoorganic changes. Personality examination 
suggested pattern of behavior, mainly in reducing volun-
tary patterns and interests, unsystematic paranoid ideas 
(of relations, influences, values, size, the sense of being 
in danger), sense of the non-realistic (altered surroun-
dings), hallucinatory sensations (‘voices’ of threatening, 
degrading and imperative character) affective dissocia-
tion (fear of people, of losing control, disintegration, 
solitude, emotional deprivation, suppressed aggressive 
energy), stereotypes in thought. 
He described having low concentration for years (resem-
bling prodromal signs of psychotic process). During the 
previous year he had been experiencing hallucinations 
and diffuse sense of being vulnerable with others (peers 
and strangers) which he ascribes to cannabis abuse”.
 Psychopharmacological therapy started with risperido-
ne and anxiolytic, and because of persistent psychotic 
symptoms clozapine therapy was also introduced. Pro-
gressively the patient’s psychological condition grew 
steady and productive symptoms reduced. His mood 
was stabilized, and overall behavior and speech became 
less disorganized. After the treatment, the patient was 
released in stable remission, with recommended con-
tinuation of regular psychiatric control and treatment. 
DISCUSSION AND CONCLUSION
In this article we have depicted an adolescent who de-
veloped florid psychotic decompensation after a long 
term use of cannabis, and in whom differential diagnosis 
discovered a diffuse atrophy of the brain uncommon at 
his age. MRI examination of the patient brain was not 
performed so we could not compare the results, but his 
MSCT scan showed an evident diffuse brain atrophy. The 
level of evidence that we possess today undoubtedly 
indicates that cannabis is bad for health and its use 
carries significant risks.
A recent study has shown reduced volume of hippo-
campus and amygdala in chronic users of cannabis, but 
there are no alterations on orbitofrontal, anterior and 
paracingulate cortices nor the pituitary gland, which adds 
to the conclusion that chronic cannabis use has a selec-
tive impact on the morphology of the mediotemporal 
lobe [16]. This is just one of a great number of studies 
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that found a noticeable neurotoxic effect of cannabis on 
certain areas of the brain, such as areas abounding in 
cannabinoid receptors – hippocampus [7] and cingula-
ted cortex [8]. Contrary studies do not find evidence of 
bad influence of cannabis [17]. They present only subtle 
morphological differences in the brain between cannabis 
users and non-users [18]. 
Possible curative effects of cannabinoids (active parts 
of cannabis) such as cannabidiol (CBD), cannabigerol 
(CBG) and tetrahydrocannabivarin (THCV) have been 
pointed out in the treatment of psychosis because of 
their antipsychotic effect [5, 6]. 
We want to emphasize that in the case of our patient the 
brain of an adolescent is different from the adult brain 
because of the incomplete maturation of its structures, 
both anatomically (neuronal connectivity and morpho-
logy) and neurochemically [10]. Chronic exposure of 
endocannabinoid system of adolescents (in this case 
a year and a half of everyday cannabis consumption 
in large amounts), may cause dramatic changes in the 
brain maturation resulting in long lasting neurobiological 
alterations and consequent changes in cognitive fun-
ctioning, with increasing risk of developing a psychotic 
disorder [11−14].
The relation of grey and white matter atrophy to the 
quantity and frequency of cannabis use has been pro-
ven [15]. In heavy cannabis smokers, grey matter of the 
brain is significantly reduced in the areas abounding in 
cannabinoid CB1 receptors [14].
No matter how controversial or dubious, the evidence 
and arguments presented in the above-mentioned stu-
dies cannot be denied. We must by all means be cautious 
in our approach and must individualize treatment of 
every patient.
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